Collegium Pharmaceutical, Inc. (COLL)
Company Info
US19459J1043
19459J104
May 7, 2015
Highlights
$947.55M
$1.22
24.16
$664.28M
$383.21M
$332.78M
$23.23 - $42.29
$41.25
16.93%
12.01
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Collegium Pharmaceutical, Inc. (COLL) returned 0.91% year-to-date (YTD) and -15.89% over the past 12 months. Over the past 10 years, COLL returned 5.45% annually, underperforming the S&P 500 benchmark at 10.82%.
COLL
0.91%
7.59%
-5.86%
-15.89%
21.95%
5.57%
5.45%
^GSPC (Benchmark)
0.12%
6.51%
-1.84%
10.98%
12.30%
14.10%
10.82%
Monthly Returns
The table below presents the monthly returns of COLL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 12.11% | -9.56% | 2.75% | -9.56% | 7.09% | 0.91% | |||||||
| 2024 | 7.08% | 11.38% | 5.75% | -4.87% | -10.26% | -2.84% | 19.78% | -0.29% | 0.47% | -11.65% | -10.66% | -6.07% | -6.92% |
| 2023 | 21.03% | -5.52% | -9.57% | -3.00% | -5.16% | -2.63% | 5.91% | 2.90% | -4.57% | -2.64% | 17.78% | 20.09% | 32.67% |
| 2022 | -4.44% | 9.08% | 4.57% | -20.92% | -2.98% | 13.44% | -2.99% | 2.27% | -8.87% | 11.99% | 21.91% | 6.08% | 24.20% |
| 2021 | 20.52% | -2.28% | 0.47% | -5.91% | 7.13% | -1.05% | 5.29% | -17.52% | -3.85% | -0.56% | -10.44% | 6.26% | -6.74% |
| 2020 | -2.26% | 18.07% | -31.24% | 26.64% | 6.62% | -20.63% | -9.83% | 20.79% | 9.23% | -14.36% | 3.70% | 8.33% | -2.67% |
| 2019 | -6.76% | 9.87% | -13.93% | -7.99% | -17.37% | 14.25% | -16.58% | 5.56% | -0.86% | 4.53% | 81.08% | -5.29% | 19.86% |
| 2018 | 29.14% | 0.63% | 6.50% | -7.44% | -4.36% | 5.44% | -19.20% | -11.26% | -13.80% | 8.89% | 19.56% | -10.53% | -6.99% |
| 2017 | 8.03% | -21.17% | -24.13% | -2.49% | -16.21% | 52.19% | -4.32% | -16.12% | 4.48% | -1.53% | 67.09% | 6.95% | 18.56% |
| 2016 | -38.07% | 2.41% | 4.07% | 5.01% | -12.28% | -29.13% | 2.36% | -31.33% | 131.21% | -22.27% | 10.62% | -5.98% | -43.38% |
| 2015 | 38.32% | 4.94% | 12.28% | -24.51% | 46.23% | -16.92% | 3.38% | 44.81% | 123.76% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of COLL is 30, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Collegium Pharmaceutical, Inc. (COLL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Collegium Pharmaceutical, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Collegium Pharmaceutical, Inc. was 73.59%, occurring on May 8, 2017. Recovery took 210 trading sessions.
The current Collegium Pharmaceutical, Inc. drawdown is 30.94%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -73.59% | Dec 31, 2015 | 340 | May 8, 2017 | 210 | Mar 8, 2018 | 550 |
| -65.22% | Mar 9, 2018 | 344 | Jul 22, 2019 | 890 | Feb 1, 2023 | 1234 |
| -41.07% | Oct 7, 2024 | 128 | Apr 10, 2025 | — | — | — |
| -35.05% | Aug 3, 2015 | 22 | Sep 1, 2015 | 9 | Sep 16, 2015 | 31 |
| -33.28% | Sep 21, 2015 | 27 | Oct 27, 2015 | 33 | Dec 14, 2015 | 60 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Collegium Pharmaceutical, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Collegium Pharmaceutical, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 2.8% positive surprise.
Valuation
The Valuation section provides an overview of how Collegium Pharmaceutical, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for COLL, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, COLL has a P/E ratio of 24.2. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for COLL compared to other companies in the Drug Manufacturers - Specialty & Generic industry. COLL currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for COLL relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, COLL has a P/S ratio of 1.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for COLL in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, COLL has a P/B value of 4.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |